🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT06287346
Recruiting Observational

5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.

NCT06287346 · tracked via the Priya Life Science Spain tracker
Sponsor
CeraRoot SL
Phase
Observational
Started
2024-01-01
Last updated
2024-03-01

Condition(s) studied

EdentulismTooth Loss

Investigational drug(s) / intervention(s)

dental implant

dental implant: ceramic dental implant

Study summary

The goal of this cohort observational study is to compare in the survival rate of ceramic dental implants placed in patients with missing or hopeless teeth . The main question\[s\] it aims to answer are:

* Are there any significant differences in survival rate between the use of one-piece ceramic implant versus the two-piece (TL) variant?
* What are the complications associated to the procedure and differences between the two groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical Diagnosis of partial or total edentulism. * Specially indicated for patients with metal allergies and chronic illness due to metal allergies. Exclusion Criteria: 1. General Contraindications: 1. Local and Systemic contraindications for surgery. 2. Poor oral hygiene 3. Patients with health problems, disease or any physical or psychological condition to which an oral surgery may be contraindicated. 2. Relative Contraindications: 1. Previously irradiated bone 2. diabetes 3. anticoagulant medication 4. hemodynamic problems 5. bruxism 6. Para functional habits 7. bad bone anatomy 8. smokers 9. none controlled periodontitis 10. malocclusions 11. TMJ problems 12. diseases in the oral cavity 13. pregnancy 14. insufficient oral hygiene for adequate health. 3. Local contraindications 1. insufficient bone quantity or quality 2. remaining of roots 3. localized periodontal disease 4. Any pathology in the neighboring teeth.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Family Holistic Dentistry Boulder Colorado Recruiting
CeraRoot CLINIC Les Franqueses del Vallès Barcelona Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06287346 on ClinicalTrials.gov ↗ ← All trials in Spain